What the new J-code means for Glaukos’ Epioxa launch and the future of keratoconus reimbursement
Glaukos secures a permanent J-code for Epioxa. Read why this reimbursement milestone could shape keratoconus treatment adoption and payer access.
Molgramostim review pushed to November: what Savara’s FDA delay means for autoimmune PAP
Savara’s molgramostim FDA review was extended to November 22, 2026. Read what this means for autoimmune PAP, launch timing, and regulatory risk.
What SurGenTec’s TiLink navigation clearance means for surgeons using minimally invasive SI joint fusion systems
SurGenTec won FDA 510(k) clearance for TiLink navigation instruments. Read what this means for SI joint fusion adoption, workflow, and competition.
Can Covalon Technologies convert IV contamination education into adoption of VALGuard and CovaClear?
Covalon Technologies is gaining momentum in vascular access and wound care. Read why its latest milestones could shape medtech growth next.
How Regenerating Skin Nectar with TriHex+ could strengthen Galderma’s aesthetics ecosystem
Galderma has launched Regenerating Skin Nectar with TriHex+. Read why this matters for peri-procedural skincare, clinics, and regenerative aesthetics.
CareDx divests Lab Products for $170m as core transplant diagnostics gains momentum
CareDx is selling its Lab Products business for $170 million. Read what the deal means for transplant diagnostics, growth focus, and execution risk.
Can Vedanta Biosciences turn microbiome therapeutics into a real prevention strategy for recurrent CDI and resistant infections?
Vedanta Biosciences unveiled VE303 and VE707 data at ESCMID 2026. Read why the microbiome strategy matters for CDI and resistant infections.
Does Verastem Oncology’s updated RAMP 201 dataset change the outlook for low-grade serous ovarian cancer treatment?
Verastem Oncology’s two-year ovarian cancer data strengthen the case for avutometinib plus defactinib. Read what this means next.
Can TECNIS PureSee help Johnson & Johnson win the next phase of premium cataract surgery?
Johnson & Johnson’s TECNIS PureSee data could reshape premium cataract surgery. Read what the ASCRS 2026 findings may change next.
Assertio-Garda deal analysis: what the Rolvedon-focused takeover means for specialty pharma investors
Find out why Assertio is being sold to Garda Therapeutics and what the Rolvedon-focused deal means for specialty pharma strategy.